Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Fig. 1

Cytotoxic effect of combination MPT0E028 with MEK inhibitors in pancreatic cancer cells. AsPC-1 (a) and PANC-1 (b) cells were treated with DMSO, MPT0E028 (E028), PD98059 (PD), or MPT0E028 plus PD98059 with indicated concentration for 72 h. AsPC-1 (c) and BxPC-3 (d) cells were treated with DMSO, MPT0E028, trametinib (T), or MPT0E028 plus trametinib with indicated concentration for 72 h. Left panels: Cell viability was determined by MTT assay. Right panels: Combination index (CI) and fraction affected (Fa) are calculated by CompuSyn software. e AsPC-1 cells were transfected with scramble or ERK siRNA and then combined with indicated concentrations of MPT0E028 for 48 h. PD 5, PD 10, PD 20, and PD 40 were represented here as PD98059 5 μM, 10 μM, 20 μM and 40 μM. T 0.3, T 1, and T 3 were represented here as trametinib 0.3 nM, 1 nM, and 3 nM

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us